Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554396 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Phase 2 study of Presbyopia, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02554396: Completed Phase 2 study of Presbyopia, sponsored by LENZ Therapeutics.
NCT02554396 is a Phase 2 study of Presbyopia that has completed, run by LENZ Therapeutics. The registered enrollment target is 20 participants, below the 270-participant average among 38 other Presbyopia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554396, a Phase 2 study of Presbyopia, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision acuity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PRX-100
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT02554396 record still lists
NCT02554396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 270-participant average among 38 other Presbyopia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02554396 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02554396 about?
NCT02554396 is a clinical study titled "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia". This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision a...
What is the current status of trial NCT02554396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-09. Estimated completion is 2015-11.
What conditions does trial NCT02554396 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT02554396?
The interventions under investigation include: Placebo (DRUG), PRX-100 (DRUG).
Who is sponsoring clinical trial NCT02554396?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02554396 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02554396's enrollment target sits among peer trials
20 35th of 38 higher than 3 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
COMPLETED · Phase 2
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Comfort and Vision With TOTAL30 Multifocal Lenses
RECRUITING
-
North American Comfilcon A Clinical Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia